492 results about "Retinal" patented technology

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The invention belongs to the technical field of biology, and discloses a capsid protein mutant capable of improving the infection ability of AAV to eye tissues and application of the capsid protein mutant. AAVRFDGTERAA and RQYSDAVRAE are inserted into amino acid at the 587 site and amino acid at the 588 site, which are equivalent to that of wild type AAV2 virus capsid protein, so that capsid protein mutants AAV2-NE01 and AAV2-NE02 are obtained. The virus yield of AAV2-NE01 and AAV2-NE02 is 1.96 times and 1.20 times that of AAV2-WT, after intravitreal injection, cells and trabecular meshwork areas of NHP retina GCL, INL to ONL can be well infected, the infection positive rate is high, the fluorescence intensity is high, the penetrating power to the retina is high, and visual cell nucleuses and inner segments can be infected. The AAV vector has a good application prospect and is expected to be developed into the AAV vector for treating eye diseases.

A composition, and uses and methods of using the composition, said composition comprising: (a) at least 0.1 wt. % of a retinoid component selected from retinol, retinal, retinoic acid or combinations thereof; (b) one or more water-soluble antioxidant; (c) one or more oil-soluble antioxidant; (d) from 0.1 to 3 wt. % of a thickener component comprising polyacrylic acid, polyacrylate, polyacrylamide, polysaccharide or combinations thereof; and (e) from 4 to 20 wt. % of an emollient component comprising a benzoic acid ester, a silicone oil, a triglyceride or a combination thereof.

The invention discloses a nucleic acid tetrahedron DNA-quercetin compound and application of the nucleic acid tetrahedron DNA-quercetin compound in treatment of retinal neovascular diseases. In the nucleic acid tetrahedron DNA-quercetin compound disclosed by the invention, a quercetin molecule is connected to one single-stranded DNA of four single-stranded DNAs of a nucleic acid tetrahedron through an azide coupling reaction. The compound is stable in physical property, quantitatively carried quercetin molecules guarantee the stability of the treatment effect of the compound, generation of new vessels can be effectively prevented, remodeling of retina non-perfusion area vessels can be promoted, retina vascular injury can be recovered, a new strategy is provided for treatment and prevention of retina neovascular diseases, and the compound is worthy of popularization and application. Meanwhile, compared with tFNAs-QUE obtained through an existing electrostatic adsorption method, the tFNAs-QUE synthesized through the azide coupling method has a better treatment effect, pathological neovascularization is greatly reduced, and meanwhile generation of physiological blood vessels in a non-vascular region is obviously promoted.

The invention relates to the technical field of medicines, in particular to a DHEA polypeptide, a sustained-release hydrogel, a coated exosome delivery preparation and application. Assembling the DHEA on the heptapeptide to obtain a DHEA polypeptide; the amino acid sequence of the heptapeptide is FFGSSSR, and the DHEA is dehydroepiandrosterone. By introducing the FFGSSSR heptapeptide with high biocompatibility, in-vitro self-assembly encapsulation of the fat-soluble drug DHEA is realized, the fat-soluble drug DHEA is prepared into an amphiphilic preparation, and the problem that the DHEA is difficult to prepare is solved; according to the invention, the exosome is introduced, and the exosome has the effect of cooperatively regulating the retina microenvironment, so that the RIR injury is treated by multiple targets; when the exosome is obtained, the R28 cells are pretreated by utilizing BBR and an anoxic condition, so that not only is the paracrine effect of the R28 cells enhanced, but also the RIR injury treatment effect of the exosome is improved.

The invention discloses a novel injection containing edaravone and high-purity synthesized (+)-2-borneol, because the (+)-2-borneol is prepared by a chemical synthesis process, the curative effect of the (+)-2-borneol is better than that of natural borneol and (+)-2-borneol extracted from the natural borneol under the same dosage, the toxic and side effects can be reduced, and the product quality is more stable; and the established GC-MS analysis method can more accurately control the content of each coexisting substance and better guarantee the shelf life quality. The injection is more suitable for improving the treatment effect on central nervous system diseases, oxidative stress injuries such as diabetes, retinopathy, diabetic peripheral neuropathy and neurodegenerative diseases and thrombus-related diseases.

The invention belongs to the technical field of biological medicine, and discloses an application of CDH5 protein and / or SELL protein as a biomarker in preparation of a kit for detecting diabetic retinopathy, the biomarker comprises at least one of CDH5 protein and SELL protein; the amino acid sequence of the CDH5 protein is as shown in SEQ NO: 1, and the amino acid sequence of the SELL protein is as shown in SEQ NO: 2. The CDH5 protein and / or the SELL protein are / is used as the biomarker for detecting diabetic retinopathy, especially for detecting early diabetic retinopathy, good sensitivity and specificity can be obtained, the accuracy of a detection result is ensured, early diagnosis and early treatment are realized, sampling is convenient and non-invasive, and large-scale popularization can be realized.

The invention provides a composition which comprises two components, and the component A comprises lutein; and the component B comprises a berry fruit extract containing anthocyanin. The composition has the effects of eliminating free radicals, resisting oxidation, protecting eyes, inhibiting tear secretion reduction, relieving eyestrain and eye dryness, relieving ciliary muscle tension, repairing retina, preventing and controlling ocular axes, protecting eyesight, preventing myopia, improving eye microcirculation, improving couperose skin and the like.

The present invention provides methods of treating ocular disorders with modulators of the WNT signaling pathway. In particular the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.

Provided herein are methods of treating diabetic retinopathy in a subject, comprising administering to the subject a compound of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein.

Provided herein are methods and apparatuses for analyzing mixed formulations of proteins and protein conjugates thereof. Some embodiments of the protein can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy.

The invention relates to the technical field of nutritional supplements, and discloses a pet nutritional supplement capable of improving immunity, which is prepared from the following raw materials in parts by weight: 35 to 45 parts of taurine, 5 to 8 parts of natural lutein, 10 to 30 parts of chondroitin sulfate, 10 to 20 parts of water, 20 to 30 parts of corn starch, 10 to 20 parts of semen plantaginis and 30 to 50 parts of microbial fermentation products. The 35-45 parts of taurine and the 10-30 parts of chondroitin sulfate can be selected from one or more of sardine powder, black and white fish powder, beef powder, pig powder, chicken powder and the like. According to the pet nutritional supplement capable of improving immunity and the preparation method thereof, the semen plantaginis is added into the raw materials, so that the pet kidney can be promoted to generate more urine, urethra flushing is facilitated, bacterium breeding is reduced, and urinary system infection is prevented, and the taurine is added, so that heart condition improvement, brain development promotion and retina protection are facilitated. When the pet supplement is prepared, the pet supplement is prepared by using a freeze-drying machine, so that the loss of nutrient substances is reduced.

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.

The invention belongs to the technical field of marine microorganisms, and discloses an application of Propionibacterium fredenreici subsp. Schermani NHNK-616 in preparation of a product for improving macular retinae, the Propionibacterium fredenreici subsp. Schermani NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the Propionibacterium fredenreici subsp. Schermani NHNK-616 is CCTCC NO: M 20241429. The invention further discloses a preparation method of the Propionibacterium fredenreici subsp. Schermani NHNK-616. The inventor finds that the NHNK-616 has the functions of improving the oxidation resistance of the retina, increasing the retinal barrier, reducing retinal neovascularization, reducing retinal inflammation and the like, in addition, an NHNK-616 thallus biological membrane can improve the colonization capacity of nasal epithelial cells and intestinal epithelial cells, and the NHNK-616 can be used for preparing products for improving the retina macular.

Provided herein are compounds of formula (I'): or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, wherein n,p, R1a, R1b, R1c, R1d, R2, R3, R4, L1, L2, L3, X1, X2, X3, X4, and X5 are as defined herein. Also provided are methods of preparing compounds of formula (I'), or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition, such as kidney disease or diabetic retinopathy, in an individual.

The invention provides a traceable mitochondrial targeting nano system as well as a preparation method and application thereof, and belongs to the field of medicines. The traceable mitochondrial targeting nano system constructed by the invention can continuously release resveratrol and maintain the photochemical stability of resveratrol. The nano system shows efficient cellular uptake and accurate mitochondrial targeting ability, and promotes removal of mitochondrial ROS and adjustment of mitochondrial autophagy, so that vascular leakage and angiogenesis are relieved, in-vivo microvascular hyperplasia and retina degeneration are remarkably inhibited, and the curative effect is improved. The distribution of the compound in fundus can be monitored in real time through clinical ophthalmological diagnosis equipment, and the compound has a good application prospect in preparation of drugs for preventing and / or treating diabetic retinopathy.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

A trace element supplement consisting of lutein, zeaxanthin, astaxanthin, anthocyanins, and proanthocyanidins is designed to improve retinal health in children and adolescents, relieve eye strain, and slow the progression of myopia. The daily dose is 1–20 mg lutein, 0.2–4 mg zeaxanthin, 0.5–8 mg astaxanthin, 10–700 mg taurine, and 0.5–8.5 mg zinc; the nighttime dose is 1–100 mg eyebright extract, 10–300 mg chamomile extract, 1–200 mg anthocyanins, and 1–500 mg proanthocyanidins.

Methods of treating anterior or vitreous chamber ocular diseases by administering ophthalmic pharmaceutical compositions of roflumilast topically to the ocular surface of the eye of a patient. The methods involving topical administration of ophthalmic pharmaceutical compositions of roflumilast to the ocular surface of a patient three or four times a day at more frequent and higher concentration, which can provide significant therapeutic activity to the anterior and vitreous chamber compartments of the eye using dosing regimens involving higher concentrations and less frequent administration than other treatment regimens.

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.

Compositions and methods diagnose and / or treat chronic kidney disease (CKD) using one or more feline circulating proteins as markers for early-stage CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), cathelicidin (CAMP), kinesin-like protein (KIF12), plasma retinol-binding protein (RBP4), Ig-like domain-containing protein (ZKSCAN1), coagulation factor X (F10), fibronectin (FN1) and mixtures thereof. The method also includes performing comparison of the amount of each of the at least one circulating protein from the feline to a corresponding predetermined value or a corresponding predetermined range. The method also includes diagnosing the feline as having early-stage CKD or not having early-stage CKD, based on the comparison.

The invention provides a gene therapy drug for treating AMD (Amplified Maleic Disease). The invention provides an anti-VEGF fusion protein with a specific secretion signal peptide sequence. The anti-VEGF fusion protein can effectively express and secrete an anti-VEGF protein. The invention also provides a modified AAV vector for improving the retinal transduction efficiency of the anti-VEGF protein. The fusion protein and the modified AAV vector can be used for treating neovascular eye diseases.

The present invention discloses a method for culturing vitreoretinal organoids in vitro, comprising the following steps: (1) amplifying and culturing pluripotent stem cells to a cell confluence of 50% to 90%; (2) on day 0, digesting the stem cells with a digestion solution; adding a neurosphere culture medium for culturing; adding matrigel for culturing, and then adding a neurosphere culture medium for culturing to obtain a cell suspension; (3) adding a ROCK pathway inhibitor to the cell suspension, and culturing in the neurosphere culture medium for 3 to 5 days to obtain ectoderm neurospheres; (4) replacing the neurosphere culture medium with a vitreous culture medium I, adding TGFB1 protein, and placing the cell suspension on a shaker for 25 to 28 days; (5) replacing the vitreous culture medium I with a vitreous culture medium II, and culturing the cell suspension for 60 to 300 days to obtain vitreoretinal organoids. The vitreous organoids of the retina cultured in vitro according to the present invention can simulate the vitreous in vivo.

Disclosed herein are methods of treating a retinal degenerative disease comprising administering to an individual in need thereof a vector comprising AIMP2-DX2 and optionally a miR-142 target sequence.

The invention relates to a supramolecular nano gene vector as well as a preparation method and application thereof. The supramolecular nano-carrier is prepared from beta-cyclodextrin grafted polyethyleneimine, 8-adamantane grafted polyamide-amine dendrimer, adamantane grafted polyethylene glycol and adamantane grafted polyethylene glycol modified by using a cell penetrating peptide (TAT). A CRISPR / Cas9 system is loaded through self-assembly of a nano material monomer, the prescription is screened, and the subsequent research on cells and retinal organs proves that the transfection efficiency and the RS1 protein expression quantity are good. The supramolecular nanoparticle loaded gene editing system has a good potential of treating the X-linked retina cleavage disease. Moreover, the supramolecular nanoparticle gene vector is high in biological safety, high in transfection efficiency, simple and easily available in preparation mode, and good in clinical application potential in the future.

Provided herein are compounds of formula (I'): or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, wherein X1, X2, X3, X4, R1, R2, Y1, Y2, Y3, m,p, r, s, t, and ring A are as defined herein. Also provided are methods of preparing compounds of formula (I), or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing. Also provided are methods of inhibiting AP0L1 and methods of treating an AP0L1 -mediated disease, disorder, or condition, such as kidney disease or diabetic retinopathy, in an individual.

The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and / or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

The invention discloses a nutritional food capable of improving a night vision function and a preparation method of the nutritional food. The composition is prepared from anthocyanin-sterculia nobilis acid nano-particles, fucoxanthin-vitamin A-resveratrol nano-particles and zinc taurate. The functions of retinal rod cells can be remarkably improved, the blood microcirculation of eyes can be promoted, and the vision sensitivity and the asthenopia resistance in dark environments such as night, weak light and low visibility can be remarkably improved; the product can be prepared into capsules, tablets, electuary, oral liquid or beverage.

The invention relates to gene therapy of ocular conditions. Described herein are compositions and methods for delivering therapeutic products, such as therapeutic proteins (e.g., antibodies), therapeutic RNAs (e.g., shRNAs, siRNAs, and miRNAs), and therapeutic aptamers, to the retinal / vitreous humor of the eye of a human subject to treat ocular conditions, involving, for example, recombinant viral vectors, such as recombinant adeno-associated virus (rAAV) vectors.